Capecitabine in the management of colorectal cancer.

Published

Journal Article

5-Fluorouracil has been a mainstay in the treatment of colorectal cancer for nearly five decades; however, the use of oral formulations of the medication has been gaining increasing traction since capecitabine was approved for use in adjuvant settings by the US Food and Drug Administration in 2005. The use of capecitabine has since spread to a number of off-label indications, including the treatment of advanced or metastatic colorectal cancer and the neoadjuvant treatment of rectal cancer. In light of increasing utilization, it is critical that clinicians have a firm understanding of the literature supporting capecitabine across various settings as well as the attributes of the drug, such as its dosing recommendations, side-effect profile, and use in the elderly. The purpose of this review is to synthesize the literature in a fashion that can be used to help guide decisions. In a setting of increasing focus on cost, the pharmacoeconomic literature is also briefly reviewed.

Full Text

Duke Authors

Cited Authors

  • Hirsch, BR; Zafar, SY

Published Date

  • 2011

Published In

Volume / Issue

  • 3 /

Start / End Page

  • 79 - 89

PubMed ID

  • 21629830

Pubmed Central ID

  • 21629830

Electronic International Standard Serial Number (EISSN)

  • 1179-1322

Digital Object Identifier (DOI)

  • 10.2147/CMR.S11250

Language

  • eng

Conference Location

  • New Zealand